These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23203815)

  • 1. Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration.
    Hoffmann M; Kasserra C; Reyes J; Schafer P; Kosek J; Capone L; Parton A; Kim-Kang H; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):489-501. PubMed ID: 23203815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.
    Chen N; Wen L; Lau H; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):789-97. PubMed ID: 22037879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
    Hoffmann M; Kumar G; Schafer P; Cedzik D; Capone L; Fong KL; Gu Z; Heller D; Feng H; Surapaneni S; Laskin O; Wu A
    Xenobiotica; 2011 Dec; 41(12):1063-75. PubMed ID: 21859393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
    Darwish M; Nunez R; Youakim JM; Robertson P
    Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass balance, metabolic disposition, and pharmacokinetics of [
    Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, Mass Balance, and Biotransformation of [
    Ni S; Ma S; Yu Y; Yu Z; Zhu Y; Sun X; Li L; Sun C; Wang H; Peng P; Gu Z; Zhang H; Wu F; Miao L; Fan J
    Drugs R D; 2024 Sep; 24(3):465-476. PubMed ID: 39231890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
    Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
    Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.
    Wright LC; Maia J; Loureiro AI; Almeida L; Soares-Da-Silva P
    Drug Metab Lett; 2010 Aug; 4(3):149-62. PubMed ID: 20642448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
    James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, absorption, metabolism, and excretion of [
    Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H
    Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [
    Zhou S; Shao F; Xu Z; Wang L; Jin K; Xie L; Chen J; Liu Y; Zhang H; Ou N
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):563-573. PubMed ID: 28730290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers.
    Miao Z; Sun H; Liras J; Prakash C
    Drug Metab Dispos; 2012 Mar; 40(3):568-78. PubMed ID: 22187487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
    Li Y; Liu L; Wang X; Zhang C; Reyes J; Hoffmann M; Palmisano M; Zhou S
    J Clin Pharmacol; 2018 Oct; 58(10):1295-1304. PubMed ID: 29762875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
    Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
    Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
    Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
    Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.